A new study published in Clinical Nutrition has identified 15 reported cases of Wernicke encephalopathy, a rare neurological disorder caused by severe vitamin B1 deficiency, in individuals taking GLP-1 receptor agonist medications, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). The findings, drawn from the FDA’s Adverse Event Reporting System (FAERS), published medical literature, and a single medical center, highlight a potential but unconfirmed risk associated with these widely prescribed drugs.
Most patients in the reported cases experienced gastrointestinal symptoms such as weight loss, vomiting, loss of appetite, or malnutrition, which may contribute to vitamin B1 deficiency. The study notes that reports of Wernicke encephalopathy appeared more frequently among GLP-1 medication users compared to those taking other drugs, though researchers caution that the data does not establish a causal link between the medications and the condition.
Key Details on Wernicke Encephalopathy
Wernicke encephalopathy is a serious neurological disorder that can lead to confusion, difficulty walking, balance problems, and vision changes. If untreated, it may result in permanent brain damage or death. Vitamin B1 (thiamine) is essential for brain function, and severe deficiencies are typically associated with malnutrition or alcohol misuse. The study suggests that the gastrointestinal side effects of GLP-1 drugs—such as reduced appetite and vomiting—could impair nutrient absorption, potentially triggering the deficiency.
Expert Perspective on Risk Assessment
Karthik Achari, a Chicago-based clinician and founder of PepMD who was not involved in the study, emphasized the rarity of the reported cases. “Researchers identified 15 cases out of millions of people taking these medications,” Achari told Fox News Digital. He described the condition as “real and serious” but noted that the mechanism linking GLP-1 drugs to Wernicke encephalopathy is plausible given their impact on appetite and nutrition.
GLP-1 medications, which include brands like Ozempic, Wegovy, Mounjaro, and Zepbound, are FDA-approved for treating type 2 diabetes and, in some cases, obesity. Their popularity has surged due to their effectiveness in promoting weight loss and improving metabolic health. However, the study’s authors and external experts stress that the 15 reported cases represent an extremely low incidence rate and do not conclusively prove a direct cause-and-effect relationship.
What Happens Next?
The FDA’s Adverse Event Reporting System relies on voluntary submissions from healthcare providers, patients, and manufacturers, meaning the data may not capture all instances of Wernicke encephalopathy linked to GLP-1 drugs. The study’s authors call for further research to clarify whether a definitive connection exists and to identify which patients may be at higher risk.
For now, healthcare professionals are urged to monitor patients on GLP-1 medications for signs of malnutrition or neurological symptoms, particularly those with pre-existing conditions that could exacerbate vitamin deficiencies. Patients experiencing severe gastrointestinal side effects are advised to consult their doctors to assess their nutritional status and adjust their treatment plans if necessary.